United Therapeutics Corpo... (UTHR)

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations acr...

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company's revenue is heavily reliant ...

Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Cha...

UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates.

United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvas...